Pharvaris Announces the Promotion of Annick Deschoolmeester to Chief Human Resources Officer
September 30 2022 - 6:50AM
Pharvaris (Nasdaq: PHVS), a clinical-stage company developing
novel, oral bradykinin-B2-receptor antagonists to treat and prevent
hereditary angioedema (HAE) attacks, today announced the promotion
of Annick Deschoolmeester to Chief Human Resources Officer. Ms.
Deschoolmeester will be responsible for overseeing Pharvaris’
people strategy, including talent acquisition and management,
employee relations, leadership development, compensation and
benefits, and diversity and inclusion.
“Annick’s deep experience in human resources, specifically
within strategic organizational growth, has had an immediate and
substantial impact on Pharvaris,” said Berndt Modig, Chief
Executive Officer of Pharvaris. “In the past year, Annick has been
instrumental to positioning Pharvaris for its next stage in scale
and impact. I look forward to her continued contributions as a key
member of our Executive Committee.”
Ms. Deschoolmeester joined Pharvaris in September 2021 as the
Head of Human Resources with over 25 years of experience in human
resources across various industries, including in management
consulting and international talent management in the biotech and
pharmaceutical industries. Before joining Pharvaris, she served as
Global Head of Learning & Talent and as HR Business Leader,
Plasma Derived Therapies, with Takeda Pharmaceuticals. Prior to
that, Ms. Deschoolmeester developed a broad human resources
background, working in human resources leadership roles at
European, international, and global levels with companies such as
Shire Pharmaceuticals, Allergan, Yahoo, and PricewaterhouseCoopers.
She holds a master’s degree in Interpreting from the Provincial
Hogeschool voor Vertalers & Tolken in Gent, Belgium.
About PharvarisPharvaris is a clinical-stage
company developing novel, oral bradykinin-B2-receptor antagonists
to treat and prevent HAE attacks, building on its deep-seated roots
in HAE. By directly targeting this clinically proven therapeutic
target with novel small molecules, the Pharvaris team aspires to
offer people with all sub-types of HAE effective and convenient
alternatives to treat attacks, both on-demand and prophylactically.
The company brings together the best talent in the industry with
deep expertise in rare diseases and HAE. For more information,
visit https://pharvaris.com/.
Forward-Looking StatementsThis press release
contains certain forward-looking statements that involve
substantial risks and uncertainties. All statements contained in
this press release that do not relate to matters of historical fact
should be considered forward-looking statements, including, without
limitation, statements containing the words “believe,”
“anticipate,” “expect,” “estimate,” “may,” “could,” “should,”
“would,” “will,” “intend” and similar expressions. These
forward-looking statements are based on management’s current
expectations, are neither promises nor guarantees, and involve
known and unknown risks, uncertainties and other important factors
that may cause Pharvaris’ actual results, performance or
achievements to be materially different from its expectations
expressed or implied by the forward-looking statements. Such risks
include but are not limited to the following: uncertainty in the
outcome of our interactions with regulatory authorities, including
the FDA with respect to the clinical hold on PHA121 clinical trials
in the U.S.; the expected timing, progress, or success of our
clinical development programs, especially for PHVS416 and PHVS719,
which are in mid-stage global clinical trials and are currently on
hold in the U.S. as a result of the clinical hold; risks associated
with the COVID-19 pandemic, which may adversely impact our
business, nonclinical studies, and clinical trials; the timing of
regulatory approvals; the value of our ordinary shares; the timing,
costs and other limitations involved in obtaining regulatory
approval for our product candidates PHVS416 and PHVS719, or any
other product candidate that we may develop in the future; our
ability to establish commercial capabilities or enter into
agreements with third parties to market, sell, and distribute our
product candidates; our ability to compete in the pharmaceutical
industry and with competitive generic products; our ability to
market, commercialize and achieve market acceptance for our product
candidates; our ability to raise capital when needed and on
acceptable terms; regulatory developments in the United States, the
European Union and other jurisdictions; our ability to protect our
intellectual property and know-how and operate our business without
infringing the intellectual property rights or regulatory
exclusivity of others; our ability to manage negative consequences
from changes in applicable laws and regulations, including tax
laws, our ability to successfully remediate the material weakness
in our internal control over financial reporting and to maintain an
effective system of internal control over financial reporting;
changes in general market, political and economic conditions,
including as a result of the current conflict between Russia and
Ukraine; and the other factors described under the headings
“Cautionary Statement Regarding Forward-Looking Statements” and
“Item 3. Key Information—D. Risk Factors” in our Annual Report on
Form 20-F and other periodic filings with the Securities and
Exchange Commission.
These and other important factors could cause actual results to
differ materially from those indicated by the forward-looking
statements made in this press release. Any such forward-looking
statements represent management’s estimates as of the date of this
press release. New risks and uncertainties may emerge from time to
time, and it is not possible to predict all risks and
uncertainties. While Pharvaris may elect to update such
forward-looking statements at some point in the future, Pharvaris
disclaims any obligation to do so, even if subsequent events cause
its views to change. These forward-looking statements should not be
relied upon as representing Pharvaris’ views as of any date
subsequent to the date of this press release.
ContactMaryann CiminoDirector of Corporate
Relationsmaryann.cimino@pharvaris.com +1-617-710-7305
Pharvaris NV (NASDAQ:PHVS)
Historical Stock Chart
From Mar 2024 to Apr 2024
Pharvaris NV (NASDAQ:PHVS)
Historical Stock Chart
From Apr 2023 to Apr 2024